T1	CHEM 57 66	ibrutinib
#1	AnnotatorNotes T1	C3501358; ibrutinib; Organic Chemical · Pharmacologic Substance
T2	CHEM 86 95	rituximab
#2	AnnotatorNotes T2	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 105 117	lenalidomida
#3	AnnotatorNotes T3	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T4	CHEM 122 131	rituximab
#4	AnnotatorNotes T4	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	CHEM 134 144	bortezomib
#5	AnnotatorNotes T5	C1176309; bortezomib; Organic Chemical · Pharmacologic Substance
T6	CHEM 149 158	rituximab
#6	AnnotatorNotes T6	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T7	PROC 167 178	tratamiento
#7	AnnotatorNotes T7	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T8	DISO 182 210	linfoma de células del manto
#8	AnnotatorNotes T8	C4721414; Mantle cell lymphoma; Neoplastic Process
T9	PROC 258 343	Estudio de fase 2/3 aleatorizado, controlado, abierto, multicéntrico e ininterrumpido
T10	CHEM 347 356	ibrutinib
#9	AnnotatorNotes T10	C3501358; ibrutinib; Organic Chemical · Pharmacologic Substance
T11	CHEM 376 385	rituximab
#10	AnnotatorNotes T11	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T12	CHEM 427 439	lenalidomida
#11	AnnotatorNotes T12	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T13	CHEM 444 453	rituximab
#12	AnnotatorNotes T13	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T14	CHEM 456 466	bortezomib
#13	AnnotatorNotes T14	C1176309; bortezomib; Organic Chemical · Pharmacologic Substance
T15	CHEM 471 480	rituximab
#14	AnnotatorNotes T15	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T16	LIVB 485 494	pacientes
#15	AnnotatorNotes T16	C0030705; Patients; Patient or Disabled Group
T17	DISO 499 527	linfoma de células del manto
#16	AnnotatorNotes T17	C4721414; Mantle cell lymphoma; Neoplastic Process
T18	DISO 577 593	Cáncer de sangre
#17	AnnotatorNotes T18	C0376545; Hematologic Neoplasms; Neoplastic Process
T19	DISO 620 648	Linfoma de células del manto
#18	AnnotatorNotes T19	C4721414; Mantle cell lymphoma; Neoplastic Process
T20	LIVB 703 720	Pacientes adultos
T21	Age 713 720	adultos
T22	DISO 725 728	LCM
#19	AnnotatorNotes T22	C0023418; leukemia; Neoplastic Process | C4721414; Mantle cell lymphoma; Neoplastic Process
T23	PROC 753 775	régimen de tratamiento
T24	DISO 791 794	LCM
#20	AnnotatorNotes T24	C0023418; leukemia; Neoplastic Process | C4721414; Mantle cell lymphoma; Neoplastic Process
T25	Neg_cue 795 805	excluyendo
T26	CHEM 806 810	BTKi
T27	Negated 806 810	BTKi
T28	DISO 813 840	Progresión de la enfermedad
#21	AnnotatorNotes T28	C0242656; Disease Progression; Pathologic Function
T29	DISO 843 850	recaída
#22	AnnotatorNotes T29	C2825055; Recurrence (disease attribute); Pathologic Function
T30	PROC 878 889	tratamiento
#23	AnnotatorNotes T30	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T31	DISO 900 903	LCM
#24	AnnotatorNotes T31	C0023418; leukemia; Neoplastic Process | C4721414; Mantle cell lymphoma; Neoplastic Process
T32	DISO 907 936	Enfermedad ganglionar medible
T33	PROC 949 965	Función orgánica
T34	PROC 975 978	CNA
T35	PROC 991 1000	Plaquetas
T36	ANAT 1009 1016	células
#25	AnnotatorNotes T36	C0007634; Cells; Cell | C1269647; Entire cell; Cell
T37	PROC 1022 1033	Hemoglobina
#26	AnnotatorNotes T37	C0518015; Hemoglobin measurement; Laboratory Procedure
T38	PROC 1043 1046	ALT
#27	AnnotatorNotes T38	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T39	PROC 1047 1050	AST
#28	AnnotatorNotes T39	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T40	PROC 1060 1077	Bilirrubina total
#29	AnnotatorNotes T40	C0201913; Bilirubin, total measurement; Laboratory Procedure
T41	PROC 1089 1093	CrCl
T42	PROC 1133 1140	Terapia
#30	AnnotatorNotes T42	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T43	CHEM 1152 1156	BTKi
T44	PROC 1159 1166	Terapia
#31	AnnotatorNotes T44	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T45	CHEM 1178 1190	Lenalidomida
#32	AnnotatorNotes T45	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T46	CHEM 1193 1203	Bortezomib
#33	AnnotatorNotes T46	C1176309; bortezomib; Organic Chemical · Pharmacologic Substance
T47	PROC 1206 1219	Cirugía mayor
#34	AnnotatorNotes T47	C0679637; major surgery; Therapeutic or Preventive Procedure
T48	Duration 1235 1244	4 semanas
T49	DISO 1259 1264	ictus
#35	AnnotatorNotes T49	C0038454; Cerebrovascular accident; Disease or Syndrome
T50	DISO 1267 1290	hemorragia intracraneal
#36	AnnotatorNotes T50	C0151699; Intracranial Hemorrhage; Pathologic Function
T51	Duration 1294 1305	los 6 meses
T52	PROC 1322 1336	aleatorización
#37	AnnotatorNotes T52	C0034656; Randomization; Research Activity
T53	DISO 1339 1375	Linfoma del sistema nervioso central
T54	DISO 1378 1399	Trastorno hemorrágico
#38	AnnotatorNotes T54	C0019087; Hemorrhagic Disorders; Disease or Syndrome
T55	DISO 1402 1427	Enfermedad cardiovascular
#39	AnnotatorNotes T55	C0007222; Cardiovascular Diseases; Disease or Syndrome
T56	DISO 1469 1477	arritmia
#40	AnnotatorNotes T56	C0003811; Cardiac Arrhythmia; Disease or Syndrome
T57	Neg_cue 1478 1480	no
T58	Negated 1481 1491	controlada
T59	DISO 1495 1528	insuficiencia cardíaca congestiva
#41	AnnotatorNotes T59	C0018802; Congestive heart failure; Disease or Syndrome
T60	DISO 1595 1615	infarto de miocardio
#42	AnnotatorNotes T60	C0027051; Myocardial Infarction; Disease or Syndrome | C0155626; Acute myocardial infarction; Disease or Syndrome
T61	DISO 1617 1633	angina inestable
#43	AnnotatorNotes T61	C0002965; Angina, Unstable; Disease or Syndrome
T62	DISO 1636 1660	síndrome coronario agudo
#44	AnnotatorNotes T62	C0948089; Acute Coronary Syndrome; Disease or Syndrome
T63	Duration 1676 1681	1 año
T64	PROC 1694 1708	aleatorización
#45	AnnotatorNotes T64	C0034656; Randomization; Research Activity
T65	Duration 1716 1732	superior a 1 año
T66	PROC 1750 1771	consulta cardiológica
#46	AnnotatorNotes T66	Cardiovascular examination and evaluation C0436125
T67	ANAT 1809 1816	corazón
#47	AnnotatorNotes T67	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T68	DISO 1820 1823	HTA
#48	AnnotatorNotes T68	C0020538; Hypertensive disease; Disease or Syndrome
T69	Neg_cue 1824 1826	no
T70	Negated 1827 1837	controlada
T71	PROC 1843 1854	tratamiento
#49	AnnotatorNotes T71	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T72	CHEM 1867 1891	medicamentos para la HTA
T73	PROC 1893 1905	PA sistólica
T74	PROC 1909 1916	cribado
#50	AnnotatorNotes T74	C0220908; Screening procedure; Diagnostic Procedure | C1698960; research subject screening; Research Activity | C1710031; Disease Screening; Diagnostic Procedure
T75	PROC 1930 1943	PA diastólica
#51	AnnotatorNotes T75	C1305849; Diastolic blood pressure measurement; Diagnostic Procedure
T76	PROC 1956 1980	Terapia contra el cáncer
#52	AnnotatorNotes T76	C0920425; cancer treatment; Therapeutic or Preventive Procedure
T77	PROC 1993 2006	quimioterapia
#53	AnnotatorNotes T77	C0013216; Pharmacotherapy; Therapeutic or Preventive Procedure | C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T78	PROC 2008 2020	radioterapia
#54	AnnotatorNotes T78	C0041626; Ultraviolet Therapy; Therapeutic or Preventive Procedure | C1522449; Therapeutic radiology procedure; Therapeutic or Preventive Procedure
T79	CHEM 2042 2054	monoclonales
#55	AnnotatorNotes T79	C0003250; Monoclonal Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
T80	CHEM 2079 2100	anticuerpo monoclonal
#56	AnnotatorNotes T80	C0003250; Monoclonal Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
T81	CHEM 2103 2127	agentes en investigación
T82	Duration 2128 2136	≤21 días
T83	CHEM 2168 2175	fármaco
#57	AnnotatorNotes T83	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T84	DISO 2265 2284	Infección sistémica
#58	AnnotatorNotes T84	C0243026; Sepsis; Disease or Syndrome
T85	Neg_cue 2292 2294	no
T86	Negated 2295 2305	controlada
T87	DISO 2318 2328	enfermedad
#59	AnnotatorNotes T87	Life threatening illness (C3846017)
T88	DISO 2359 2369	enfermedad
#60	AnnotatorNotes T88	Life threatening illness (C3846017)
T89	DISO 2400 2416	condición médica
#61	AnnotatorNotes T89	C4745084; Medical Condition; Finding
T90	DISO 2419 2454	disfunción de un sistema de órganos
#62	AnnotatorNotes T90	Organ dysfunction syndrome C0342953
T91	LIVB 2475 2487	investigador
#63	AnnotatorNotes T91	C0035173; Research Personnel; Professional or Occupational Group
T92	Spec_cue 2489 2494	pueda
T93	Speculated 2495 2519	comprometer la seguridad
T94	LIVB 2524 2536	participante
T95	PHYS 2557 2566	absorción
T96	PHYS 2590 2599	absorción
T97	PHYS 2605 2616	metabolismo
#64	AnnotatorNotes T97	C0025519; Metabolism; Organism Function
T98	CHEM 2620 2629	ibrutinib
#65	AnnotatorNotes T98	C3501358; ibrutinib; Organic Chemical · Pharmacologic Substance
T99	DISO 2642 2659	diabetes mellitus
#66	AnnotatorNotes T99	C0011849; Diabetes Mellitus; Disease or Syndrome | C1802373; Diabetes mellitus (incl subtypes); Disease or Syndrome
T100	Neg_cue 2660 2662	no
T101	Negated 2663 2673	controlada
T102	PROC 2676 2681	HbA1C
#67	AnnotatorNotes T102	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T103	DISO 2688 2691	VIH
#68	AnnotatorNotes T103	C0458074; Human immunodeficiency virus (HIV) status; Finding
T104	DISO 2693 2731	infección activa por hepatitis B/C y E
T105	LIVB 417 423	médico
T106	Spec_cue 2539 2549	interferir
T107	Speculated 2557 2566	absorción
T108	Spec_cue 2572 2582	interferir
T109	Speculated 2590 2599	absorción
T110	Speculated 2605 2616	metabolismo
T111	CHEM 2031 2040	moléculas
T112	CHEM 2061 2069	molécula
T113	Duration 2140 2163	al menos 5 vidas medias
T114	PROC 2219 2249	administración del tratamiento
#69	AnnotatorNotes T114	Administration of medication C3469597 
T115	Observation 211 234	recidivante/refractario
T116	Observation 528 539	recidivante
T117	Observation 542 553	refractario
T118	Observation 649 660	recidivante
T119	Observation 663 674	refractario
T120	Quantifier_or_Qualifier 742 752	Al menos 1
T121	CONC 939 943	ECOG
T122	Result_or_Value 944 946	≤1
T123	Observation 949 974	Función orgánica adecuada
T124	Result_or_Value 979 990	≥ 1000/mm^3
T125	Result_or_Value 1001 1021	≥50.000 células/mm^3
T126	Result_or_Value 1034 1041	≥8 g/dL
T127	Result_or_Value 1051 1059	≤3 X ULN
T128	Result_or_Value 1078 1088	≤1,5 X ULN
T129	Result_or_Value 1094 1104	≥30 mL/min
T130	Quantifier_or_Qualifier 1428 1454	clínicamente significativa
T131	Quantifier_or_Qualifier 1481 1491	controlada
T132	Result_or_Value 1532 1543	clase II-IV
T133	Quantifier_or_Qualifier 1827 1837	controlada
T134	Quantifier_or_Qualifier 1859 1866	3 o más
T135	Result_or_Value 1917 1927	>160 mm Hg
T136	Result_or_Value 1944 1953	>100mm Hg
T137	Quantifier_or_Qualifier 2285 2291	activa
T138	Quantifier_or_Qualifier 2295 2305	controlada
T139	Observation 2333 2357	ponga en peligro la vida
T140	Observation 2374 2398	ponga en peligro la vida
T141	Observation 2495 2519	comprometer la seguridad
T142	CONC 2539 2549	interferir
T143	CONC 2572 2582	interferir
T144	Quantifier_or_Qualifier 2663 2673	controlada
T145	Result_or_Value 2682 2685	>7)
T146	Other 417 423	médico
T147	Patient 485 494	pacientes
T148	Patient 703 720	Pacientes adultos
T149	History_of 753 760	régimen
T150	History_of 764 775	tratamiento
T151	History_of 806 810	BTKi
T152	History_of 878 889	tratamiento
T153	History_of 1133 1140	Terapia
T154	History_of 1152 1156	BTKi
T155	History_of 1159 1166	Terapia
T156	History_of 1178 1190	Lenalidomida
T157	History_of 1193 1203	Bortezomib
T158	History_of 1206 1219	Cirugía mayor
T159	History_of 1259 1264	ictus
T160	History_of 1267 1290	hemorragia intracraneal
T161	History_of 1595 1615	infarto de miocardio
T162	History_of 1617 1633	angina inestable
T163	History_of 1636 1660	síndrome coronario agudo
T164	Other 2475 2487	investigador
T165	Patient 2524 2536	participante
